8-K: Alumis and ACELYRIN Announce Merger to Create Late-Stage Biopharma Company Focused on Immune-Mediated Diseases

Alumis and ACELYRIN will merge in an all-stock transaction to create a company with a late-stage clinical pipeline targeting immune-mediated diseases.

Summary

• Alumis and ACELYRIN have entered into a definitive merger agreement for an all-stock transaction.
• The merger aims to create a late-stage clinical biopharma company focused on developing and commercializing therapies for immune-mediated diseases.
• ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned.
• Upon closing, Alumis stockholders will own approximately 55% and ACELYRIN stockholders will own approximately 45% of the combined company on a fully diluted basis.
• The combined company will have a pro forma cash position of approximately $737 million as of December 31, 2024, expected to provide runway into 2027.
• The merger is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The combined company will operate under the Alumis name, led by the current Alumis executive team, and will be headquartered in South San Francisco.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the potential benefits of the combined company. However, there are also risks and uncertainties associated with the transaction, which temper the overall sentiment.

Positives

• The merger creates a company with a stronger financial position and a more diversified pipeline.
• The combined company expects to have sufficient cash to fund operations into 2027, beyond multiple key data readouts.
• The merger brings together complementary expertise in drug development and commercialization.
• The combined company will have a late-stage portfolio of therapies targeting a broad range of immune-mediated diseases.

Negatives

• ACELYRIN intends to delay initiation of its Phase 3 LONGITUDE program for lonigutamab in thyroid eye disease until the closing of the Merger.
• The merger is subject to stockholder approval and customary closing conditions, which could delay or prevent the transaction from closing.

Risks

• The merger may not be completed in a timely manner or at all.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• The combined company may face challenges in integrating the operations and personnel of Alumis and ACELYRIN.
• The combined company's product candidates may not receive regulatory approval or achieve commercial success.
• The combined company may be adversely affected by economic, business, and/or competitive factors.

Future Outlook

The combined company will focus on advancing a differentiated late-stage portfolio of therapies and leveraging its track record of R&D success to develop life-changing medicines.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, 'Through this combination with ACELYRIN, Alumis will have the financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab, and build commercial capabilities.'
• Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the Board Transaction Committee said, 'This merger represents the culmination of a thorough strategic review process by our Board and management team to determine the best and most value-maximizing path forward for ACELYRIN.'
• Mina Kim, Chief Executive Officer of ACELYRIN, said, 'This merger brings together two complementary organizations and pipelines, enabling the company to leverage the benefits of combined development and commercial expertise, as well as catalyst diversification, to achieve even more together.'

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to achieve greater scale, diversification, and financial resources to support drug development and commercialization.

Comparison to Industry Standards

• The all-stock transaction is a common structure in the biopharma industry, allowing companies to combine resources without immediate cash outlays.
• The combined company's focus on immune-mediated diseases aligns with a growing area of unmet medical need and significant market opportunity.
• The pro forma cash position of $737 million is substantial and provides a competitive advantage in funding clinical trials and commercialization efforts.
• Comparable companies in the biopharma space with similar market capitalizations and pipelines include entities such as Arcutis Biotherapeutics, Inc. and Immunovant, Inc.

Stakeholder Impact

• Shareholders of both companies will be impacted by the merger, with Alumis shareholders owning approximately 55% and ACELYRIN shareholders owning approximately 45% of the combined company.
• Employees of both companies may be affected by potential integration and restructuring efforts.
• Patients with immune-mediated diseases may benefit from the development of new therapies by the combined company.

Next Steps

• Obtain stockholder approvals from both Alumis and ACELYRIN.
• Satisfy other customary closing conditions.
• Close the transaction, expected in the second quarter of 2025.
• Integrate the operations and personnel of Alumis and ACELYRIN.
• Advance the combined company's pipeline of product candidates through clinical development.
• Re-evaluate the development program for lonigutamab to confirm differentiation in a capital efficient manner.

Key Dates